638 related articles for article (PubMed ID: 34763561)
1. Does the FT3-to-FT4 ratio easily predict the progression of NAFLD and NASH cirrhosis?
Türker F; Oral A; Şahin T; Türker BÇ; Koçak E; Ataoğlu HE; Ahbab S
J Int Med Res; 2021 Nov; 49(11):3000605211056841. PubMed ID: 34763561
[TBL] [Abstract][Full Text] [Related]
2. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
[TBL] [Abstract][Full Text] [Related]
3. FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran.
Amernia B; Moosavy SH; Banookh F; Zoghi G
BMC Gastroenterol; 2021 Dec; 21(1):453. PubMed ID: 34861841
[TBL] [Abstract][Full Text] [Related]
4. Accuracy of Noninvasive Fibrosis Scores to Detect Advanced Fibrosis in Patients With Type-2 Diabetes With Biopsy-proven Nonalcoholic Fatty Liver Disease.
Singh A; Gosai F; Siddiqui MT; Gupta M; Lopez R; Lawitz E; Poordad F; Carey W; McCullough A; Alkhouri N
J Clin Gastroenterol; 2020; 54(10):891-897. PubMed ID: 32168133
[TBL] [Abstract][Full Text] [Related]
5. Low Free Triiodothyronine Is Associated with Advanced Fibrosis in Patients at High Risk for Nonalcoholic Steatohepatitis.
Manka P; Bechmann L; Best J; Sydor S; Claridge LC; Coombes JD; Canbay A; Moeller L; Gerken G; Wedemeyer H; Syn WK
Dig Dis Sci; 2019 Aug; 64(8):2351-2358. PubMed ID: 31155687
[TBL] [Abstract][Full Text] [Related]
6. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
Patel YA; Gifford EJ; Glass LM; Turner MJ; Han B; Moylan CA; Choi S; Suzuki A; Provenzale D; Hunt CM
Dig Dis Sci; 2018 Sep; 63(9):2259-2266. PubMed ID: 29779083
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
[TBL] [Abstract][Full Text] [Related]
8. Mediating effect analysis of visceral adiposity index on free triiodothyronine to free thyroxine ratio and non-alcoholic fatty liver disease in euthyroid population.
Liu HX; Ren YY; Meng CQ; Li Z; Nie Q; Yu CH; Ma HJ
Front Endocrinol (Lausanne); 2022; 13():961803. PubMed ID: 36105392
[TBL] [Abstract][Full Text] [Related]
9. Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels.
Gawrieh S; Wilson LA; Cummings OW; Clark JM; Loomba R; Hameed B; Abdelmalek MF; Dasarathy S; Neuschwander-Tetri BA; Kowdley K; Kleiner D; Doo E; Tonascia J; Sanyal A; Chalasani N;
Am J Gastroenterol; 2019 Oct; 114(10):1626-1635. PubMed ID: 31517638
[TBL] [Abstract][Full Text] [Related]
10. Free triiodothyronine is associated with the occurrence and remission of nonalcoholic fatty liver disease in euthyroid women.
Chen P; Hou X; Wei L; Feng L; Zhong L; Jiao L; Wang H; Bao Y; Jia W
Eur J Clin Invest; 2019 Apr; 49(4):e13070. PubMed ID: 30636282
[TBL] [Abstract][Full Text] [Related]
11. Factors predicting non-alcoholic steatohepatitis (NASH) and advanced fibrosis in patients with non-alcoholic fatty liver disease (NAFLD).
Tasneem AA; Luck NH; Majid Z
Trop Doct; 2018 Apr; 48(2):107-112. PubMed ID: 29145775
[TBL] [Abstract][Full Text] [Related]
12. Assessment of liver fibrosis using non-invasive screening tools in individuals with diabetes mellitus and metabolic syndrome.
Shaji N; Singhai A; Joshi R
J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443467
[TBL] [Abstract][Full Text] [Related]
13. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
Verma S; Jensen D; Hart J; Mohanty SR
Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360
[TBL] [Abstract][Full Text] [Related]
14. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
[No Abstract] [Full Text] [Related]
15. Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage.
Siddiqui MS; Yamada G; Vuppalanchi R; Van Natta M; Loomba R; Guy C; Brandman D; Tonascia J; Chalasani N; Neuschwander-Tetri B; Sanyal AJ;
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1877-1885.e5. PubMed ID: 30616027
[TBL] [Abstract][Full Text] [Related]
16. Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies.
Reddy YK; Marella HK; Jiang Y; Ganguli S; Snell P; Podila PSB; Maliakkal B; Satapathy SK
J Clin Exp Hepatol; 2020; 10(3):245-254. PubMed ID: 32405181
[TBL] [Abstract][Full Text] [Related]
17. Validation model of fibrosis-8 index score to predict significant fibrosis among patients with nonalcoholic fatty liver disease.
Prasoppokakorn T; Chan WK; Wong VW; Pitisuttithum P; Mahadeva S; Nik Mustapha NR; Wong GL; Leung HH; Sripongpun P; Treeprasertsuk S
World J Gastroenterol; 2022 Apr; 28(15):1563-1573. PubMed ID: 35582126
[TBL] [Abstract][Full Text] [Related]
18. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.
Bazick J; Donithan M; Neuschwander-Tetri BA; Kleiner D; Brunt EM; Wilson L; Doo E; Lavine J; Tonascia J; Loomba R
Diabetes Care; 2015 Jul; 38(7):1347-55. PubMed ID: 25887357
[TBL] [Abstract][Full Text] [Related]
19. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
Newsome PN; Sasso M; Deeks JJ; Paredes A; Boursier J; Chan WK; Yilmaz Y; Czernichow S; Zheng MH; Wong VW; Allison M; Tsochatzis E; Anstee QM; Sheridan DA; Eddowes PJ; Guha IN; Cobbold JF; Paradis V; Bedossa P; Miette V; Fournier-Poizat C; Sandrin L; Harrison SA
Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):362-373. PubMed ID: 32027858
[TBL] [Abstract][Full Text] [Related]
20. Steatosis severity affects the diagnostic performances of noninvasive fibrosis tests in nonalcoholic fatty liver disease.
Joo SK; Kim W; Kim D; Kim JH; Oh S; Lee KL; Chang MS; Jung YJ; So YH; Lee MS; Bae JM; Kim BG
Liver Int; 2018 Feb; 38(2):331-341. PubMed ID: 28796410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
